



"Express Mail" mailing number: ED775634385 US

Date of Deposit October 10, 2006

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Oksana Buynitzky
Oksana Buynitzky

Date of Signature October 10, 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gilboa et al.

Group Art Unit: 1633

Serial No.: 10/613,262

Examiner: Wehbe, Anne Marie Sabrina

Filed: July 3, 2003

Docket No.: 1430/13

Confirmation No.: 3315

For: **ANGIO-IMMUNOTHERAPY**

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that the references are relevant merely because cited.

Appln. No.: 10/613,262

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a Final Action or the Notice of Allowance.

Early passage of the subject application to issue is earnestly solicited.

A check in the amount of \$605.00 (representing the \$425.00 additional claims fee and \$180.00 Information Disclosure Statement fee) is enclosed. The Commissioner is authorized to charge any deficiencies of payment associated with the filing of this correspondence to Deposit Account No. 50-0426 to avoid the unintentional abandonment of the instant application.

Respectfully submitted,

JENKINS, WILSON, TAYLOR, & HUNT, P.A.

Date: October 10, 2006

By:



Arles A. Taylor, Jr.
Registration No. 39,395

AAT/AD/omb

Enclosures

Customer No. **25297**



FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 1430/13	Serial No. 10/613,262
List of Documents Cited by Applicant		
Applicant(s): Gilboa et al.		
Filing Date: July 3, 2003		Group 1633

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	A	BACHMANN et al. <i>Protection Against Immunopathological Consequences of a Viral Infection by Activated but not Resting Cytotoxic T Cells: T Cell Memory Without "Memory T Cells"</i> <i>Proceedings of The National Academy of Sciences USA</i> , Vol. 94, (1997), pp. 640-645
	B	BAILAR III et al. <i>Cancer Undefeated</i> <i>The New England Journal of Medicine</i> , Vol. 336, No. 22, (1997), pp. 1569-1574
	C	BLANCHER et al. <i>The Molecular Basis of the Hypoxia Response Pathway: Tumour Hypoxia as a Therapy Target</i> <i>Cancer and Metastasis Review</i> , Vol. 17, (1998), pp. 187-194

EXAMINER _____ DATE CONSIDERED _____

*ExaminerInitial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 1430/13	Serial No. 10/613,262
List of Documents Cited by Applicant			
		Applicant(s): Gilboa et al.	
		Filing Date: July 3, 2003	Group 1633
	D	BOCZKOWSKI et al. <i>Dendritic Cells Pulsed with RNA are Potent Antigen-Presenting Cells in Vitro and in Vivo</i> <i>Journal of Experimental Medicine</i> , Vol. 184, (1996), pp. 465-472	
	E	BROSTJAN et al. <i>Monitoring of Circulating Angiogenic Factors in Dendritic Cell-Based Cancer Immunotherapy</i> <i>Cancer</i> , Vol. 98, No. 10, (2003), pp. 2291-2301	
	F	CHENG et al. <i>Tumor-Specific Immunity and Antiangiogenesis Generated by a DNA Vaccine Encoding Calreticulin Linked to a Tumor Antigen</i> <i>The Journal of Clinical Investigation</i> , Vol. 108, No. 5, (2000), pp. 669-678	
	G	CHERRINGTON et al. <i>New Paradigms for the Treatment of Cancer: The Role of Anti-Angiogenesis Agents</i> <i>Advances in Cancer Research</i> , Vol. 79, (2000), pp. 1-38	
	H	CRYSTAL, Ronald G. <i>In Vivo and Ex Vivo Gene Therapy Strategies to Treat Tumors Using Adenovirus Gene Transfer Vectors</i> <i>Cancer Chemother Pharmacol</i> , Vol. 43, (1999), pp. S90-S99	
	I	DEPLANQUE et al. <i>Anti-Angiogenic Agents: Clinical Trial Design and Therapies in Development</i> <i>European Journal of Cancer</i> , Vol. 36, (2000), pp. 1713-1724	
	J	EATOCK et al. <i>Tumour Vasculature as a Target for Anticancer Therapy</i> <i>Cancer Treatment Reviews</i> , Vol. 26, (2000), pp. 191-204	
	K	GABRILOVICH et al. <i>Production of Vascular Endothelial Growth Factor by Human Tumors Inhibits the Functional Maturation of Dendritic Cells</i> <i>Nature Medicine</i> , Vol. 2, No. 10, October (1996), pp. 1096-1103	
	L	GALE et al. <i>Growth Factors Acting Via Endothelial Cell-Specific Receptor Tyrosine Kinases: VEGFs, Angiopoietins, and Ephrins in Vascular Development</i> <i>Genes & Development</i> , Vol. 13, (1999), pp. 1055-1066	
	M	GILBOA, Eli. <i>The Makings of a Tumor Rejection Antigen</i> <i>Immunity</i> , Vol. 11, (1999), pp. 263-270	

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 1430/13	Serial No. 10/613,262
List of Documents Cited by Applicant			
		Applicant(s): Gilboa et al.	
		Filing Date: July 3, 2003	Group 1633
	N	HANAHAH, Douglas. <i>Signaling Vascular Morphogenesis and Maintenance Science</i> , Vol. 277, (1997), pp. 48-50	
	O	HANAHAH et al. <i>Patterns and Emerging Mechanisms of the Angiogenic Switch During Tumorigenesis Cell</i> , Vol.86, August 9, (1996), pp. 353-364	
	P	HEISER et al. <i>Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses in Vitro The Journal of Immunology</i> , Vol. 164, (2000), pp. 5508-5514	
	Q	KERBEL, Robert S. <i>A Cancer Therapy Resistant to Resistance Nature</i> , Vol. 390, (1997), pp. 335-336	
	R	LANGE-ASSCHENFELDT et al. <i>The Angiogenesis Inhibitor Vasostatin Does not Impair Wound Healing at Tumor-Inhibiting Doses Journal of Investigative Dermatology</i> , Vol. 117, (2001), pp. 1036-1041	
	S	LI et al. <i>Active Immunization Against the Vascular Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and Metastasis Journal of Experimental Medicine</i> , Vol. 195, No. 12, (2002), pp. 1575-1584	
	T	LIN et al. <i>Antiangiogenic Gene Therapy Targeting the Endothelium-Specific Receptor Tyrosine Kinase Tie2 Proceedings of the National Academy of Sciences USA</i> , Vol. 95, (1998), pp. 8829-8834	
	U	LIN et al. <i>Inhibition of Tumor Angiogenesis Using a Soluble Receptor Establishes a Role for Tie2 in Pathologic Vascular Growth Journal of Clinical Investigation</i> , Vol. 100, No. 8, (1997), pp. 2072-2078	
	V	MINEV et al. <i>Cytotoxic T Cell Immunity Against Telomerase Reverse Transcriptase in Humans Proceedings of the National Academy of Sciences USA</i> , Vol. 97, No. 9, (2000), pp. 4796-4801	

EXAMINER _____ DATE CONSIDERED _____

*ExaminerInitial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 1430/13	Serial No. 10/613,262
List of Documents Cited by Applicant			
		Applicant(s): Gilboa et al.	
		Filing Date: July 3, 2003	Group 1633
	W	NAIR et al. <i>Induction of Primary Carcinoembryonic Antigen (CEA)-specific Cytotoxic T Lymphocytes in Vitro Using Human Dendritic Cells Transfected with RNA</i> <i>Nature Biotechnology</i> , Vol. 16, (1998), pp. 364-369	
	X	NAIR et al. <i>RNA-Transfected Dendritic Cells</i> <i>Expert Review of Vaccines</i> , Vol. 1, No. 4, (2002), pp. 507-513	
	Y	NAIR et al. <i>Induction of Cytotoxic T Cell Responses and Tumor Immunity Against Unrelated Tumors Using Telomerase Reverse Transcriptase RNA Transfected Dendritic Cells</i> <i>Nature Medicine</i> , Vol. 6, No. 8, (2000), pp. 1011-1017	
	Z	NIETHAMMER et al. <i>A DNA Vaccine Against VEGF Receptor 2 Prevents Effective Angiogenesis and Inhibits Tumor Growth</i> <i>Nature Medicine</i> , Vol. 8, No. 12, (2002), pp. 1369-1375	
	AA	PARDOLL, Drew M. <i>Cancer Vaccines</i> <i>Nature Medicine Vaccine Supplement</i> , Vol. 4, No. 5, (1998), pp. 525-531	
	AB	QUINN et al. <i>CM101, a Polysaccharide Antitumor Agent, Does Not Inhibit Wound Healing in Murine Models</i> <i>Journal of Cancer Research and Clinical Oncology</i> , Volume 121, (1995), pp. 253-356	
	AC	ROSENBERG, Steven A. <i>Progress in Human Tumour Immunology and Immunotherapy</i> <i>Nature</i> , Vol. 411, (2001), pp. 380-384	
	AD	SAEBOE-LARSEN et al. <i>mRNA-based Electroporation of Human Dendritic Cells and Induction of Cytotoxic T Lymphocyte Responses Against the Telomerase Catalytic Subunit (hTERT)</i> <i>Journal of Immunological Methods</i> , Vol. 259, (2002), pp. 191-203	
	AE	SCHREURS et al. <i>Dendritic Cells Break Tolerance and Induce Protective Immunity Against a Melanocyte Differentiation Antigen in an Autologous Melanoma Model</i> <i>Cancer Research</i> , Vol. 60, (2000), pp. 6995-7001	

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 1430/13	Serial No. 10/613,262
List of Documents Cited by Applicant			
		Applicant(s): Gilboa et al.	
		Filing Date: July 3, 2003	Group 1633
	AF	SIEMEISTER et al. <i>Two Independent Mechanisms Essential for Tumor Angiogenesis: Inhibition of Human Melanoma Xenograft Growth by Interfering with Either the Vascular Endothelial Growth Factor Receptor Pathway or the Tie-2 Pathway</i> <i>Cancer Research</i> , Vol. 59, (1999), pp. 3185-3191	
	AG	VEIKKOLA et al. <i>VEGFs, Receptors and Angiogenesis</i> <i>Seminars in Cancer Biology</i> , Vol. 9, (1999), pp. 211-220	
	AH	VONDERHEIDE et al. <i>The Telomerase Catalytic Subunit is a Widely Expressed Tumor-Associated Antigen Recognized by Cytotoxic T Lymphocytes</i> <i>Immunity</i> , Vol. 10, (1999), pp. 673-679	

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.